Literature DB >> 30837278

Delirium management by palliative medicine specialists: a survey from the association for palliative medicine of Great Britain and Ireland.

Jason W Boland1, Monisha Kabir2, Shirley H Bush2,3,4, Juliet Anne Spiller5,6, Miriam J Johnson7, Meera Agar6, Peter Lawlor2,3,4.   

Abstract

OBJECTIVES: Delirium is common in palliative care settings. Management includes detection, treatment of cause(s), non-pharmacological interventions and family support; strategies which are supported with varying levels of evidence. Emerging evidence suggests that antipsychotic use should be minimised in managing mild to moderate severity delirium, but the integration of this evidence into clinical practice is unknown.
METHODS: A 21-question online anonymous survey was emailed to Association for Palliative Medicine members in current clinical practice (n=859), asking about delirium assessment, management and research priorities.
RESULTS: Response rate was 39%: 70% of respondents were palliative medicine consultants. Delirium guidelines were used by some: 42% used local guidelines but 38% used none. On inpatient admission, 59% never use a delirium screening tool. Respondents would use non-pharmacological interventions to manage delirium, either alone (39%) or with an antipsychotic (58%). Most respondents (91%) would prescribe an antipsychotic and 6% a benzodiazepine, for distressing hallucinations unresponsive to non-pharmacological measures. Inpatient (57%) and community teams (60%) do not formally support family carers. Research priorities were delirium prevention, management and prediction of reversibility.
CONCLUSION: This survey of UK and Irish Palliative Medicine specialists shows that delirium screening at inpatient admission is suboptimal. Most specialists continue to use antipsychotics in combination with non-pharmacological interventions to manage delirium. More support for family carers should be routinely provided by clinical teams. Further rigorously designed clinical trials are urgently needed in view of management variability, emerging evidence and perceived priorities for research. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  assessment; cognition; delirium management; palliative care; palliative medicine; research

Mesh:

Year:  2019        PMID: 30837278     DOI: 10.1136/bmjspcare-2018-001586

Source DB:  PubMed          Journal:  BMJ Support Palliat Care        ISSN: 2045-435X            Impact factor:   3.568


  4 in total

1.  Improving the Detection, Assessment, Management and Prevention of Delirium in Hospices (the DAMPen-D study): protocol for a co-design and feasibility study of a flexible and scalable implementation strategy to deliver guideline-adherent delirium care.

Authors:  Mark Pearson; Gillian Jackson; Catriona Jackson; Jason Boland; Imogen Featherstone; Chao Huang; Margaret Ogden; Kathryn Sartain; Najma Siddiqi; Maureen Twiddy; Miriam Johnson
Journal:  BMJ Open       Date:  2022-07-13       Impact factor: 3.006

2.  Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.

Authors:  Katarina Rukavina; Victor McConvey; Kallol Ray Chaudhuri; Janis Miyasaki
Journal:  Int Rev Neurobiol       Date:  2022-04-27       Impact factor: 4.280

3.  Validation of the 4AT tool for delirium assessment in specialist palliative care settings: protocol of a prospective diagnostic test accuracy study [version 1; peer review: 2 approved].

Authors:  Elizabeth Arnold; Anne M Finucane; Juliet A Spiller; Zoë Tieges; Alasdair M J MacLullich
Journal:  AMRC Open Res       Date:  2021-04-26

4.  The experience of delirium in palliative care settings for patients, family, clinicians and volunteers: A qualitative systematic review and thematic synthesis.

Authors:  Imogen Featherstone; Annmarie Hosie; Najma Siddiqi; Pamela Grassau; Shirley H Bush; Johanna Taylor; Trevor Sheldon; Miriam J Johnson
Journal:  Palliat Med       Date:  2021-03-30       Impact factor: 4.762

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.